NeuroSense Therapeutics
NRSN
5 hedge funds and large institutions have $243K invested in NeuroSense Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
485% more capital invested
Capital invested by funds: $41.6K → $243K (+$202K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
0.75% more ownership
Funds ownership: 0.3% → 1.05% (+0.75%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$158K |
| 2 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$19.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$22K |
| 2 |
Morgan Stanley
New York
|
-$5 |
NRSN Hedge Fund Activity: Q1 2023 in Review
5 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q1 2023, worth a combined $243K — up 485% from $41.6K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NRSN positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Meitav Investment House, opening a new position worth an estimated $158K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $22K sold.
- 5 institutional investors held NeuroSense Therapeutics (NRSN) as of Q1 2023, up from 4 in Q4 2022.
- Funds reported $243K of NeuroSense Therapeutics stock for Q1 2023, up 485% quarter-over-quarter.
- 2 funds opened new NeuroSense Therapeutics positions in Q1 2023 and 1 closed out, a net change of +1 holder.
- The largest NeuroSense Therapeutics buyer in Q1 2023 was Meitav Investment House, an estimated $158K added.
- The largest NeuroSense Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $22K sold.
Based on aggregated 13F filings for Q1 2023.